Rhythm Pharmaceuticals Inc (RYTM)
43.71
+1.43
(+3.38%)
USD |
NASDAQ |
Jul 08, 16:00
43.71
0.00 (0.00%)
After-Hours: 18:56
Rhythm Pharmaceuticals SG&A Expense (Annual): 117.53M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 117.53M |
| December 31, 2022 | 92.03M |
| December 31, 2021 | 68.49M |
| December 31, 2020 | 46.12M |
| December 31, 2019 | 36.55M |
| Date | Value |
|---|---|
| December 31, 2018 | 28.08M |
| December 31, 2017 | 9.518M |
| December 31, 2016 | 6.311M |
| December 31, 2015 | 3.425M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
36.55M
Minimum
2019
117.53M
Maximum
2023
72.14M
Average
68.49M
Median
2021
SG&A Expense (Annual) Benchmarks
| Pfizer Inc | 14.77B |
| Amgen Inc | 6.179B |
| Amicus Therapeutics Inc | 275.27M |
| Viking Therapeutics Inc | 37.02M |
| Arvinas Inc | 100.30M |